AbbVie Reports Second-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Francisco Partners to acquire Weave Communications for $650M
AbbVie (ABBV) climbs after raising full-year earnings guidance
July 27, 2023 9:09 AM EDTAbbVie (NYSE: ABBV) shares are climbing premarket on the back of its second-quarter profit and revenue beat. The company also raised earnings per share guidance.
The pharmaceutical firm reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter... More
AbbVie (ABBV) Tops Q2 EPS by 4c, Raises FY Guidance
July 27, 2023 7:39 AM EDTAbbVie (NYSE: ABBV) reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.87 billion versus the consensus estimate of $13.51 billion.
GUIDANCE:
AbbVie sees FY2023 EPS of $10.90-$11.10, versus the consensus of $10.85.
Raises 2023... More